ReviewExpert opinion on biological therapy2009
Elite control of HIV infection: implications for vaccine design.
Review in Expert opinion on biological therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00908323 (Characterization of the Innate Immune Response to Candidate HIV Vaccines, an Ancillary Study to HVTN 205), which is not on this map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Characterization of the Innate Immune Response to Candidate HIV Vaccines, an Ancillary Study to HVTN 205
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 120 citations in OpenAlex.
- A systematic review of definitions of extreme phenotypes of HIV control and progression.AIDS (London, England) · 2014Pooled it
- MVA.HIVconsvX vaccination-evoked T cell expansion inversely associates with age in people with HIV-1 on antiretroviral therapy.The Journal of clinical investigation · 2026Trial
- Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial.Journal of acquired immune deficiency syndromes (1999) · 2013Trial
- HIV-1 superinfection occurs less frequently than initial infection in a cohort of high-risk Kenyan women.PLoS pathogens · 2013Trial
- Transient plasma viral rebound after SARS-CoV-2 vaccination in an exceptional HIV-1 elite controller woman.Virology journal · 2023Article
- Plasma metabolomics by nuclear magnetic resonance reveals biomarkers and metabolic pathways associated with the control of HIV-1 infection/progression.Frontiers in molecular biosciences · 2023Article
- Infectious RNA: Human Immunodeficiency Virus (HIV) Biology, Therapeutic Intervention, and the Quest for a Vaccine.Toxins · 2022Review
- HIV specific CD8Frontiers in immunology · 2022Article
- Functional cure of a chronic virus infection by shifting the virus - host equilibrium state.Frontiers in immunology · 2022Article
- Long noncoding RNA MIR4435-2HG enhances metabolic function of myeloid dendritic cells from HIV-1 elite controllers.The Journal of clinical investigation · 2021Article
- A high prevalence of potential HIV elite controllers identified over 30 years in Democratic Republic of Congo.EBioMedicine · 2021Article
- The Search for an HIV Cure: Where Do We Go From Here?The Journal of infectious diseases · 2021Article
- HLA-B*27:05 alters immunodominance hierarchy of universal influenza-specific CD8+ T cells.PLoS pathogens · 2020Article
- Lessons Learned From Failures and Success Stories of HIV Breakthroughs: Are We Getting Closer to an HIV Cure?Frontiers in microbiology · 2020Review
- T Cell Therapy Targeted on HLA-A02 Restricted HIV Antigen Epitopes: An Open Label Cellular Therapy Trial Using CD8+ T Cell.Frontiers in immunology · 2019Article
- Temporal variation in HIV-specific IgG subclass antibodies during acute infection differentiates spontaneous controllers from chronic progressors.AIDS (London, England) · 2018Article
- Case report: mechanisms of HIV elite control in two African women.BMC infectious diseases · 2018Article
- Article
- Plasma Levels of Complement Factor I and C4b Peptides Are Associated with HIV Suppression.ACS infectious diseases · 2017Article
- HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIV.Journal of virology · 2017Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
background'Elite controllers' are rare HIV-infected individuals who are able to spontaneously control HIV replication without medication, maintaining viral loads that are consistently below the limits of detection by currently available commercial assays.
objectiveTo examine studies of elite controllers that may elucidate mechanisms of HIV immune control useful in designing a vaccine.
methodsRecent literature on HIV controllers and studies that have evaluated aspects of viral and host immunology that correlate with viral control are examined. RESULTS/
conclusionsAlthough many elements of innate and adaptive immunity are associated with control of HIV infection, the specific mechanism(s) by which elite controllers achieve control remain undefined. Ongoing studies of elite controllers, including those examining host genetic polymorphisms, should facilitate the definition of an effective HIV-specific immune response and guide vaccine design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.